

Datasheet for ABIN2666752
CCL28 Protein (AA 23-130)



[Go to Product page](#)

Overview

Quantity:	25 µg
Target:	CCL28
Protein Characteristics:	AA 23-130
Origin:	Mouse
Source:	Escherichia coli (E. coli)
Protein Type:	Recombinant
Biological Activity:	Active
Application:	Flow Cytometry (FACS)

Product Details

Purity:	> 98 % , as determined by Coomassie stained SDS-PAGE.
Sterility:	0.22 µm filtered
Endotoxin Level:	Less than 0.01 ng per µg cytokine as determined by the LAL method.

Target Details

Target:	CCL28
Alternative Name:	CCL28 (CCL28 Products)
Background:	Mouse CCL28 was identified in an EST database using a human chemokine consensus sequence. CCL28 is constitutively expressed by mucosal epithelial cells such as exocrine glands, trachea, and colon. Acinar epithelial cells in human and mouse salivary glands are strongly positive for CCL28 by immunostaining, and human saliva and milk contain high

Target Details

concentrations of CCL28. Furthermore, it is known that human and mouse CCL28 have antimicrobial activity against *Candida albicans*, Gram-negative bacteria, and Gram-positive bacteria, and the the C terminus of human CCL28 is responsible for this property. In addition, using a CCR10 deficient mouse model, it was shown that CCR10 plays a critical role in localization and accumulation of IgA ASC to the lactating mammary gland. Also, it has been described that CCL28 is upregulated in epithelial inflammation and this upregulation allows the recruitment of T regs expressing CCR10. In fact, a subpopulation of CCR10-expressing CD25+CD4+Foxp3+ Tregs with potent anti-inflammatory properties was isolated from chronically inflamed human liver. Most recent information suggested that tumour hypoxia promotes the recruitment of Treg cells through induction of expression of CCL28, and this induction is mediated by the hypoxia inducible factor-1 α (HIF-1 α). Therefore, tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells.

Molecular Weight: The 109 amino acid recombinant protein has a predicted molecular mass of approximately 12.4 kDa. The DTT-reduced protein migrates at approximately 15 kDa and non-reduced protein migrates at 18 kDa by SDS-PAGE. The N-terminal amino acid is Methionine.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment: Biological activity: Bioactivity was measured by its property to chemoattract BaF3-hCCR10 transfectants in a dose dependent manner.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μ g/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HAS. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μ m filtered protein solution is in 10 mM NaH₂PO₄, 0.15 M NaCl, pH 7.2.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or

at -70°C for one year.